Improved survival with ipilimumab in patients with metastatic melanoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antigens, CD
  • Cancer Vaccines
  • Melanoma

abstract

  • Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)

authors

publication date

  • August 19, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3549297

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1003466

PubMed ID

  • 20525992

Additional Document Info

start page

  • 711

end page

  • 23

volume

  • 363

number

  • 8